Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients

Phase 3

• Conditions: Schizophrenia.; Schizophrenia

• Registration Number: IRCT20190707044123N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

The diagnosis of schizophrenia based on Diagnostic and Statistical Manual of Psychiatric Disorders (DSM5)
Patients receiving second-generation drugs
A year past diagnosis of schizophrenia
Patients have a secondary school education

Exclusion Criteria

Sensitivity to famotidine
Drug abuse
Serious medical illness (Nephrology disease)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptoms of schizophrenia. Timepoint: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention. Method of measurement: The effectiveness of the treatment will be evaluated in Baseline and Six weeks after the intervention based on the score obtained from the Wechsler Memory Scale(WMS) and Positive and Negative Symptoms of Schizophrenia(PANSS).